Acquiring Company
Astellas
Acquired Company
Propella Therapeutics, Inc.
PittsboroBiotechnologyHealth CareMedicalPharmaceuticalPharmaceutical ManufacturingPharmaceutical ManufacturingDescription
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Propella Therapeutics, Inc. (President and CEO: William Moore, "Propella") today announced that Astellas, through a U.S. subsidiary, and Propella have entered into a merger agreement pursuant to which Astellas will acquire Propella. Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.
Quick answer
Astellas is acquiring Propella Therapeutics, Inc., announced November 15, 2023.
- Who acquired Propella Therapeutics, Inc?
- Astellas agreed to acquire Propella Therapeutics, Inc. on November 15, 2023.
- How much did Astellas pay for Propella Therapeutics, Inc?
- The deal value was not disclosed.
- What does Astellas do?
- Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company.
- Where are Astellas and Propella Therapeutics, Inc. based?
- Propella Therapeutics, Inc. is based in Pittsboro, North Carolina, United States.
Source: Fundz verified event record.
Other recent acquisitions in Medical and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Lilly To Acquire Point Biopharma To Expand Oncology Capabilities Into Next-Generation Radioligand Therapies (October 3, 2023)
- Astellas Completes Acquisition Of Propella Therapeutics (December 21, 2023)
- Airlife Completes Acquisition Of Avanos Medical’S Respiratory Health Business (October 2, 2023)
- Lilly Completes Acquisition Of Point Biopharma (December 27, 2023)
- Versiti Acquires Indianapolis-Based Pearl Pathways (November 7, 2023)
- Abbvie To Acquire Cerevel Therapeutics In Transformative Transaction To Strengthen Neuroscience Pipeline (December 6, 2023)
Who to call at Astellas, and when
When Astellas changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Astellas raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Astellas, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Astellas. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Astellas makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Propella Therapeutics, Inc.?
Propella Therapeutics, Inc. was acquired by Astellas. The deal was reported on November 15, 2023. Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is privately held and operates in Biotechnology.
When did Astellas acquire Propella Therapeutics, Inc.?
Astellas's acquisition of Propella Therapeutics, Inc. was reported on November 15, 2023. Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Propella Therapeutics, Inc. (President and CEO: William Moore, "Propella") today announced that Astellas, through a U.S. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Propella Therapeutics, Inc. do?
We are a privately held development-stage company dedicated to bringing to market best-in-class drugs that utilize an active ingredient with a known mechanism of action. It is privately held, operating in Pharmaceutical Manufacturing, and is based in Pittsboro.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.